




DHC6 D-MAPP PPMP NB-DNJ (30 uM) (20 uM) (40 uM) Ceramide (20uM) **8**2 Control Myriocin C6 (1 nM) Ceramide (dpm/protein) (% control)






















Ceramide de-novo synthesis pathway

SRE-mediated gene transcription. ceramide de-novo pathway in the regulation of Overview of compounds used to investigate role of

- Inhibitors are underlined
- Enzyme in italics
- -Alternate pathways that generate DAG and that were investigated are boxed


SRE-mediated gene transcription decrease ceramide de-novo synthesis and c ramide and dihydroceramide All inhibitors of ceramide de-novo pathway,


Fumonisin B1


Ceramide synthase

Dihydroceramide

PPMP










Vesicle budding: Role of PKD and DAG -


Diacylglycerol (DAG) + PKD = vesicle budding from the TGN Resvaratro

PKD is *DAG: recruits Protein Kinase D to the trans-Golgi network (TGN) by being a target for PKD's C1a domain. ssential for the initiation of vesicle budding (Malhotra, Baron: Science Vol 292, 325 (2002).










18 h Control 10000 ₇ Cholesterol FIGURE 12 4000 2000 8000 0009 dpm / protein **Control and HSN Cells** ³H-Mevalonate **Lipid Extraction** 7 and 18 h

HSN

³H-Cholesterol








FIGURE 13

FIGURE 14




■ Total Chol ☐ Free Chol O CE 1.55 Free CHOLESTEROL, (measured by GC, 6-20-03) 26.2 25.258 4561 9.40 4513 FIGURE 15 **ug/mg protein** 35.0 30.0 25.0 10.0 5.0 0.0



HSN 4513 (control) 4 h with BSA (100 X) FIGURE 17A



HSN 4513 (control) 4 h with OA (100 X) FIGURE 17B








FIGURE 17C




HSN 4561 4 h with BSA (100 X)





HSN 4561, 4 h with 0.3 mM OA (100 X 5-20-03)

BEST AVAILABLE COPY







FIGURE 19

Ceramide de novo synthesis (black bars) is increased in NPA cells significantly after C8 ceramide (white) for 16 h. Measurement of 3 H compared to controls, slightly decreased by cholesterol (grey) and serine label over 4 h after o/n treatment




Chol + BSA

Activity

FIGURE 21

cholesterol (grey) or C8 ceramide (white) for 16 h. Measurement of Free Cholesterol synthesis (black bars) is increased in NPA cells compared to controls and equally decreased by addition of 3 H mevalonate label incorporation (lipid extraction, TLC)






FIGURE 22




FIGURE 23